文献速递骨质疏松与钙磷/甲状旁腺糖尿病肥胖与代谢综合征

司美格鲁肽与替尔泊肽对骨折高风险患者骨骼的影响

Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

单中心回顾性研究纳入255例使用司美格鲁肽或替尔泊肽至少6个月且有DXA扫描的成人患者,按年龄、性别、BMI及糖尿病状态匹配255例对照。中位随访17个月后两组全髋与股骨颈骨密度均显著下降且幅度相近;

要点

  • GLP-1RA组与对照组全髋、股骨颈骨密度下降幅度总体相似
  • 无糖尿病患者使用GLP-1RA后全髋骨丢失较对照更明显
  • 体重下降与全髋及股骨颈骨丢失相关

核心结论

  • SEM/TIR使用与无糖尿病患者更大的年化全髋骨丢失相关。
  • 糖尿病患者中GLP-1RA与对照的全髋骨丢失相近。
  • GLP-1RA对骨骼的影响可能因糖尿病状态而异,无糖尿病患者中体重下降驱动骨丢失。

研究设计与样本

  • 单中心回顾性研究。
  • GLP-1RA组255例使用SEM或TIR≥6个月,92%女性,平均年龄64±9岁,BMI 31.0±5.6 kg/m²。
  • 对照组255例按年龄、性别、BMI及糖尿病状态匹配,同期至少2次DXA扫描。
  • 主要结局为全髋骨密度百分比变化。

主要发现

  • 中位随访17个月,GLP-1RA组中位体重下降5%。
  • 两组全髋与股骨颈骨密度均显著下降,组间幅度相似。
  • GLP-1RA组体重下降与全髋及股骨颈骨丢失直接相关(全髋r=0.32,股骨颈r=0.17,均P<.01)。
  • 无糖尿病患者中GLP-1RA组全髋骨丢失大于对照(-1% vs -0.6%,P=.04)。
  • 糖尿病患者中两组全髋骨丢失相似。

临床怎么用

  • 对无糖尿病的GLP-1RA使用者应关注体重下降伴随的骨丢失并考虑骨密度监测。
  • 糖尿病患者使用SEM/TIR时全髋骨丢失与对照相近。

局限性

  • 单中心回顾性设计。
  • 样本以女性为主,外推需谨慎。
  • 仅报告全髋与股骨颈骨密度,未涉及骨折结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP1-RA) have potent glucose-lowering and weight loss benefits, but their effects on bone remain unclear. OBJECTIVE: To investigate changes in bone mineral density (BMD) in patients using semaglutide (SEM) and tirzepatide (TIR), a dual agonist of GLP-1/glucose dependent insulinotropic polypeptide. METHODS: Single-center retrospective study. Adult patients using SEM/TIR for ≥6 months with DXA scans before initiation and at least 6 months after were matched by age, sex, BMI, and diabetes mellitus (DM) to nonusers with at least 2 DXA scans over the same period. The primary outcome was the percentage change in total hip (TH) BMD. RESULTS: We included 255 patients using SEM or TIR in the GLP-1 RA group (92% female, mean age 64 ± 9 years, BMI 31.0 ± 5.6 kg/m²) and 255 controls. After a median follow-up of 17 months, the GLP-1 RA group achieved a median 5% weight loss. Both groups had significant declines in BMD at TH and FN, with a similar magnitude between groups. In the GLP-1RA group, weight loss was directly associated with bone loss at the TH and FN (r = 0.32 for TH, r = 0.17 for FN, both P < .01). Among patients without DM, greater TH bone loss was noted in the GLP-1 RA group compared to controls (-1% vs -0.6%, P = .04), whereas TH bone loss was similar between groups among patients with DM. CONCLUSION: SEM/TIR use was associated with greater annualized TH bone loss in patients without DM, whereas TH bone loss was comparable between GLP-1 RA and controls in patients with DM. These findings suggest GLP-1 RA's effects on bone may differ by DM status, with weight loss driving bone loss in patients without DM.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu Y, Walzer D, Schmitz S, et al. Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. J Clin Endocrinol Metab. 2026. PMID: 41655226. doi:10.1210/clinem/dgag052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。